Eli Lilly's Jaypirca receives FDA approval for first-line treatment of untreated CLL and SLL

Eli Lilly announced that the FDA has approved its drug Jaypirca as a first‑line therapy for patients with previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.

The approval expands the use of Jaypirca to cover both CLL and SLL in the front‑line setting, offering a new option for clinicians managing these blood cancers.

Analysts see the decision as a positive development for Lilly's oncology portfolio, potentially boosting the company's market position in hematology treatments.